COMMUNIQUÉS West-GlobeNewswire

Specific Health Guidance Service Utilizing the "Lav" Healthcare App: Surpassed 100 cumulative contracted companies and 10,000 cumulative supported individuals!
30/05/2025
TOKYO, May 30, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) ("MEDIROM," "we,” “us” or “our”), a holistic healthcare company based in Japan, announces that its subsidiary, MEDIROM MOTHER [...]
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting
30/05/2025
HANOVER, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy [...]
PharmAla Biotech Warns Against Fake Products Claiming to be Made by PharmAla
30/05/2025
TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
Legend Senior Living® Grows Portfolio Across Kansas, Colorado, and Pennsylvania
30/05/2025
WICHITA, Kan., May 30, 2025 (GLOBE NEWSWIRE) -- Legend Senior Living, a national senior housing provider headquartered in Wichita, Kansas, has announced it will assume management of four additional communities, [...]
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
30/05/2025
Fortress will receive ~$28 million shortly after closing and is eligible for an additional contingent value right (CVR) of up to $4.8 million, plus a 2.5% royalty on future net sales of UNLOXCYT™ (cosibelimab-ipdl) [...]
Immuron Letter to Shareholders: Projects Update
30/05/2025
Highlights: Immuron on track to exceed A$7 million in Sales this financial year Uniformed Services University anticipates topline results of Travelan ® clinical study in October 2025 Immuron anticipates IMM-529 ( [...]
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
30/05/2025
Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-BTC-01 clinical study $20 million [...]
Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series
30/05/2025
Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical development SOUTH SAN FRANCISCO, Calif., May 30, 2025 ( [...]
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
30/05/2025
DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil"), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced that Bronson Crouch, [...]
Ascend Aesthetic Partners Welcomes David Cutter as COO
30/05/2025
ATLANTA, May 30, 2025 (GLOBE NEWSWIRE) -- Ascend Aesthetic Partners (Ascend) is pleased to announce the addition of David Cutter as Chief Operating Officer. Cutter is a passionate leader who reflects our values of [...]
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
30/05/2025
FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today [...]
Arvinas to Present at Jefferies Global Healthcare Conference
30/05/2025
NEW HAVEN, Conn., May 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that [...]
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025
30/05/2025
PRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in June. Jefferies [...]
Conavi Medical Reports Fiscal Q2 2025 Interim Results and Operational Highlights
30/05/2025
New U.S. intracoronary imaging guidelines from the American College of Cardiology and recent peer-reviewed research strongly validate Novasight’s unique value proposition Upsized $20 million financing led by U.S. [...]
BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages
30/05/2025
New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of life RESEARCH TRIANGLE PARK, N.C., May 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc [...]
Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.
30/05/2025
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 30, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ [...]
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
30/05/2025
30 scientific abstracts will be presented using clonoSEQ for MRD assessment across multiple types of blood cancers SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a [...]
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
30/05/2025
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis [...]
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics
30/05/2025
REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., announced its name [...]

Pages